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Introduction 
According to 2011 UNAIDS statistics, the world’s AIDS epidemic 
has hit a plateau, with 2.7 million people becoming newly infected each 
year for the last five years [1]. Two-thirds of all people infected with 
HIV live in sub-Saharan Africa with severe demographic effects and 
country development impact. In this geographical area, South Africa 
and Swaziland are among the countries most affected by HIV/AIDS. 
UNAIDS has estimated that in 2009 the total number of persons living 
with HIV in South Africa was 5.7 million, a number that makes South 
Africa one of the countries with the largest HIV epidemic in the world 
[2]. Recent data also indicate that in South Africa incidence among 
men and women aged 15-49 was estimated to be 1.3/100/pyar in the 
period 2005–2008 [3]. For Swaziland, the 26% HIV prevalence in the 
adult population found in 2006 through a national population-based 
survey, is the highest ever documented [4]. Finally, South Africa and 
Swaziland are also among the countries in the world, where the number 
of recent infections is extremely high [5]. 
The development of a vaccine capable of preventing HIV infection 
and reducing virus transmission and spread would be essential to 
reduce the burden of AIDS and AIDS-related diseases, in particular in 
developing countries. However, such a preventative vaccine still remains 
a formidable challenge. One of the obstacles to its development is the 
design of an immunogen that elicits potent and broadly neutralizing 
antibodies, capable of preventing HIV infection. The primary targets 
of this neutralising response are epitopes in the HIV envelope (Env) 
that are involved in infectivity and transmission. However, attempts to 
induce these types of neutralising antibodies have failed so far [6], due 
the high variability of the Env  proteins, from different clades and in the 
same  subject, during the disease that allows the virus to escape the host 
immune response [7]. 
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Background: The development of a vaccine against HIV/AIDS capable of preventing virus infection has been 
hampered by the HIV envelope (Env) heterogeneity that makes it difficult to induce neutralizing antibodies against 
Env proteins from different HIV clades. Several studies have indicated that gp120 Env protein sequence tends to 
change considerably during the course of HIV disease which allows the virus to escape the immune responses. In 
order to define gp120 sequence changes, we have characterized the V1, V2, V4 and V5 variable regions of gp120 
variants from 72 HIV-1-clade-C-infected subjects from South Africa and Swaziland, which were naïve to antiretroviral 
(ARV) therapy and at different disease stages. Sequence characteristics, such as aminoacid sequence length, 
presence of Putative N-Glycosylation Sites (PNGSs) and electric charge were investigated. 
Methods: According to the Avidity Index value and CD4+ T cell count, patients were classified for disease stage 
in three groups: recent, chronic and late stage, each one comprised of 24 patients. The V1 to V5 Env variable regions 
were directly PCR amplified from plasma virus RNA and sequenced.
Results: A significant increase in the amino acid sequence length of V1 and V4 domains, and a corresponding 
increase of the “shifting” PNGSs were observed in the HIV variants obtained from individuals at chronic stage of 
disease, as compared to the recent infection group. Finally, a significant increase of the net electric positive charge 
of the V5 loop was found in the HIV variants from the group of subjects with late disease, as compared to the chronic 
disease group. 
Conclusion: We conclude that changes in sequence length, glycosylation pattern and net electrical charge 
in the variable V1, V4 and V5 regions of gp120 occur in the course of HIV infection, possibly in response to the 
pressure of the host immune response. 
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Genetic diversity of HIV-1 is represented by distinct subtypes or 
clades, A to K, as well as by recombinants [8]. The HIV-1 subtype C is 
prevalent in Sub-Saharan Africa and is widespread worldwide, being 
responsible of more than 52% of total HIV-1 infections [9,10].
Five loop regions of the gp120, V1 to V5, are particularly variable 
and play a major role in infectivity, transmission and resistance to 
neutralization [11-13]. Early data on HIV-1 clade B, and more recent 
data on clade C, have shown that the V1 region is highly variable, 
protects the CD4 binding-site from neutralising antibodies and may 
play a role in infectivity and tropism [14,15]. The V2 region, closely 
interacting with V1, is less variable, can bind the Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) 
[16], and also plays a role in infectivity and tropism [16,17]. The V1 
and V2 regions, together, have been shown to modulate neutralization 
sensitivity by hiding conserved epitopes, such as the coreceptor binding 
site [18-20]. The V3 region has been shown to bind both CCR5 and 
CXCR4 cellular co-receptors [21,22]. In HIV-1 subtype C viruses this 
region is more conserved than in other clades [23,24], and preferentially 
binds the CCR5 co-receptor, independently of the disease stage 
[25,26]. Finally, the function of V4 and V5 regions has not been clearly 
identified, although they are likely to influence Env conformation and 
glycan packing [27,28], thereby limiting accessibility to neutralization 
determinants by steric hindrance. In addition, some data indicate that 
epitopes in the C3-V4 region are major targets of the early autologous 
neutralizing response in HIV-1 subtype C infection [29].
HIV-1 Env gp120 is among the most heavily glycosylated 
proteins in nature [30-32]. Alterations of the glycosylation pattern 
can impact protein folding [33] and play a role in masking linear and 
conformational epitopes that are sensitive targets for neutralization 
[34]. Changes in the glycosylation pattern may also affect and influence 
co-receptor binding, thereby playing a role in viral tropism [35]. It has 
also been demonstrated that N-glycans in gp120 may play a role in viral 
transmission [11] and infectivity through the interaction between high 
mannose oligosaccharides and the DC-SIGN or other C-type lectins 
[36]. Altered patterns of glycosylation can modulate the immunogenic 
properties of the gp120 and contribute to escape from humoral and 
T-cell responses [14,37], thus providing a “shield” against the immune 
response of the host [27].
Increasing evidence, based on restricted numbers of donor/
recipient couples and individuals with acute infection, suggests that a 
few or just one single viral variant, characterized by a more compact 
gp120 Env protein, can establish the initial infection [11,38-41]. More 
recently, it has been demonstrated that primary infection may be 
mediated by viruses with relatively short variable regions of gp120 and a 
low number of PNGSs and that these variants show a higher sensitivity 
to neutralization by sera [38,42,43]. Other data indicate that variants 
from different HIV-1 clades, isolated from recently infected patients, 
show shorter V1-V2 sequences than variants isolated from chronically 
infected individuals, and that these variants are also more sensitive 
to neutralisation by patient sera than those isolated during chronic 
infection [44-46]. Finally, it has been recently reported that variations 
in the net electric charge in both variable and constant regions of the 
virus may be responsible of virus resistance to neutralisation [23,34,47]. 
Therefore, it is plausible that during the course of the disease the 
sequence characteristics of Env variable domains may have an impact 
on the selection of virus variants and on their ability to be transmitted 
and/or escape immune control. 
In order to identify key putative features of the Env sequence, we 
have performed a cross-sectional study on 72 HIV-1 clade C-infected 
individuals from Swaziland and South Africa at different disease stages, 
from whom we obtained virus variants that have been characterised 
for amino acid sequence length, glycosylation pattern and net electric 
charge of their gp120 variable regions.
Materials and Methods
Sample collection
A total of 72 plasma samples were collected in the period 2005-2007 
from HIV-positive individuals, living in the Southern Africa region, 
all naïve for Antiretroviral Therapy (ART). Samples were obtained 
from 24 individuals enrolled during the 2006 Swaziland HIV National 
Serosurvey [4], 24 individuals attending the Chris Hani Baragwanath 
Hospital (CHBH) in Soweto, Johannesburg, South-Africa, in the 
framework of the activities included in the AVIP project (www.avip-
eu.org) and 24 individuals attending the HIV/AIDS National Referral 
Laboratory (NRL) Hospital in Mbabane, Swaziland, in the framework 
of activities of projects from the Italian AIDS Programme. Ethical 
clearance for these studies was previously obtained from local Ethical 
Committees. Disease stage of each enrolled individual was determined 
on the basis of the Avidity Index [48,49] and CD4+ T cell count, as 
described in the Results section.
CD4+ T cell count 
CD4+ T cell count was performed by means of MultiTEST and 
TruCOUNT tubes (Beckton Dickinson) according to the manufacturer’s 
instructions. 
Avidity Index (AI) assay
Avidity Index Assay was performed as previously described [48,49]. 
An Index ≤0.8 identified an HIV infection occurred within 6 months 
from blood drawing (here defined as recent infection) [48,49].
Viral RNA extraction and sequence amplification
Viral RNA was extracted from 0.5 ml of plasma using Qiamp viral 
RNA miniKit (Qiagen), after treatment with Heparinase (Sigma). The 
V1-V5 coding region in the Env gene was amplified by RT-PCR using 
SuperScriptTM One-Step RT-PCR System (Invitrogen) and specifically 
designed external primers for clade C HIV-1. Primers were: AC-Env 
Outer For 5′-CAGATGCATGAGGATATAATCA-3′; ED12m Outer 
Rev 5′-AGTGCTTCCTTGCTGCTCCCAA3′. 
The RT-PCR mix was composed of 0.5 to 1 μg of RNA that were 
added to an RT/Taq buffer mixture containing 0.4 mM dATP, dCTP, 
dTTP, dGTP (Roche), 2.4 mM MgSO4 (Invitrogen), 1 µl RT/Taq-
platinum (Invitrogen), 40 U/μl of RNase inhibitor (Invitrogen), and 
10 μM primers (MWB-Biotech). Reaction was carried out in a thermal 
cycler (Eppendorf) according to the following program: 45°C for 30′, 
for retrotranscription and 94°C for 2′ for the RT denaturation; the 
resulting cDNA was amplified as follows: 94°C for 15″, 50°C for 30″ and 
68°C for 1′30″ for a total of 40 cycles. A final extension step followed 
for 7′ at 68°C.
The resulting PCR product was again amplified in a nested PCR, 
using specifically designed primers identified in conserved external 
portions enclosing each target nucleotide sequence (i.e. V1-V2, V3-
C3 and V4-C4-V5 Env regions). Primers specific for each region are 
reported in Table 1.
Each nested reaction was conducted as follows: an aliquot of 1-5 μl 
of the amplified product was added to a reaction mixture containing 
200 µM dNTPS (Roche), 2.5 mM MgCl2 (Invitrogen), the couple of 
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20 μM primers corresponding to the region that had to be amplified 
(MWB-Biotech), 2.5 U/μl of AmpliTaq Gold DNA polymerase and 1x 
AmpliTaq Buffer (Applied Biosystems). Amplifications were carried 
out specifically for each region as follows: V1-V2: 96°C for 7′, then 
15″at 94°C, 30″ at 48°C, 30″ at 72°C (for 40 cycles); V3-C3: 96°C for 7′, 
then 15″ at 94°C, 30″ at 50°C, 30″ at 72°C (for 40 cycles); V4-C4-V5: 
96°C for 7′, then 15″ at  94°C, 30″ at 44°C, 30″ at 72°C (for 40 cycles).
All these PCR reactions were followed by a final extension step of 
7′at 68°C.
DNA purification and sequencing
Amplified DNA of each region was purified using Qiaquick PCR 
purification kit (Qiagen), according to the manufacturer’s protocol. The 
DNA samples were then quantified and checked for purity by measuring 
absorbance at 260 nm and 280 nm to estimate contaminants. 
The V1-V2, V3-C3 and V4-C4-V5 amplified nucleotide sequences 
were then sequenced according to the Sanger method [50] using the 
same primers as nested PCR.
Sequence analysis
Sequencing was performed on uncloned PCR products to identify 
the prevalent viral quasispecies. The electropherogram was edited 
using Chromas Pro (www.techelsium.com.au/ChromasPro.html). All 
sequences were aligned using Clustal X [51] and corrected for multiple 
alignment by manual editing.
The nucleotide sequences were translated into aminoacid 
sequences using GeneRunner (www.generunner.net) and further 
codon-aligned using BioEdit [52]. The V1, V2 and V1-V2 regions were 
defined as sequences comprised between the corresponding HXBc2 
envelope aminoacids 131 to 157, 158 to 196 and 131 to 196, respectively 
(Accession number AAB50262-1, Geneprot). The V3 region was 
defined as the sequence comprised between the corresponding HXBc2 
envelope aminoacids 296 to 331. The V4 and V5 regions were defined 
as sequences comprised between the corresponding HXBc2 envelope 
aminoacids 385 to 418 and 460 to 471, respectively.
The identification of PNGSs in V1, V2, V3, V4 and V5 regions was 
performed by using N-GLYCOSYTE (http://www.hiv.lanl.gov/content/
sequence/ GLYCOSITE/glycosite.html). The analysis of predicted co-
receptor usage on V3 region was performed by using Geno2pheno 
(http://coreceptor.bioinf.mpi-inf.mpg.de/index.php).
Phylogenetic analysis was carried out using the PAUP software 
(version 4.0) [53] with the K81 model of substitution and by the use 
of both Neighbor-Joining (NJ) and Maximum Likelihood (ML) tree-
building methods. The evolutionary model was chosen as the best-
fitting nucleotide substitution model in accordance with the results 
of the Hierarchical Likelihood Ratio Test (HLRT) implemented in 
MODELTEST software (version 3.6) [54].
The parameters for the nucleotide substitution model were 
estimated by the ML method using a NJ tree (Jukes-Cantor distance) 
as the base tree [55].
The statistical robustness and reliability of the branching order 
within phylogenetic trees were confirmed by either a bootstrap analysis 
using 1000 replicates, for the NJ tree, or the zero branch length tests 
for the ML tree. All calculations were performed with PAUP software 
(version 4.0) [53]. 
In order to evaluate genetic distances among sequences from 
variants isolated during the three disease stages, the Mega 4 program 
(www.megasoftware.net) with Kimura 2 model was used.
HIV group M subtypes and CRFs sequences were available at the 
Los Alamos database (www.hiv.lanl.gov/content/hiv-db/ALIGN_
CURRENT/ALIGN-INDEX.html).
Statistical analysis
The Wilcoxon rank sum test was used to compare the differences 
between the groups of recently infected individuals, patients with 
chronic disease and patients at late disease stage, for each one of the 
parameters analysed in the study. 
Furthermore, to measure existing correlation between sequence 
length and glycosylation status, a linear regression, using Spearman’s 
correlation test, was performed (Stata 8.2). 
For the electric charge analysis of each region, the algebraic sum 
of all charged residues, both positive and negative, was considered as 
the total electric charge (Qtot), whereas the sums of all the positive 
charged residues (Arg, Lys, Hys) and of all negative charged residues 
(Glu, Asp) were considered as total positive (Qpos) and total negative 
(Qneg) charge, respectively. An original Matlab program was written 
to yield the distribution of Qtot, Qpos and Qneg directly from the * 
fas files with the aligned sequences. Such distributions were analyzed 
with Wilcoxon’s rank sum test, after a preliminary checking of the non-
Gaussian nature of the distributions using the Kolmogorov-Smirnov 
test, as previously described [56].
Results 
The 72 HIV-1-infected patients from Swaziland and South Africa, 
all naïve for antiretroviral therapy, were classified for the disease stage 
in three groups: Recent Stage (RS), Chronic Stage (CS), and Late Stage 
(LS), on the basis of the AI assay and the CD4+T cell count. An AI 
≤ 0.80 identified samples from recently infected individuals with stage 
(RS), [48,49], whereas patients with chronic and late disease (CS and 
LS, respectively) were identified on the basis of an AI > 0.80 and CD4+ 
T cell counts. Specifically, patients with CD4+ T cell count ≤ 200/µl 
were considered to be at a late stage of disease, whereas the group of 
patients with chronic disease was identified by CD4+ T cell counts > 
200/µl (Table 2). 
A Maximum Likelihood (ML) phylogenetic tree, based on the V3-
V5 coding region, classified all variants obtained from the patients 
ENV Region Primers I Primers II
V1-V2 ForA 5’ACCCCACTCTGTGTCACTTT3’
RevA 5’TATTACACTTTAGAATCGCA3’
ForB 5’AAGTTGACCCCACTCTGTGT3’
RevB 5’CTTTAGAATCGCATAACCAG 3’
V3-C3 ForA 5’CTGTTAAATGGTAGCCTAGC3’ 
RevA 5’GCAATAGAAAAATTCTCC3’
ForB 5’CACAGTACAATGTACACATG3’ 
RevB 5’RCAATAGAAAAATTCTCCTC3’
V4-C4-V5 ForA 5’GTRGAGGAGAATTTTTCTATTG3’ 
RevA 5’TATAATTCACTTCTCCARTTGTC3’
ForB 5’ TTTAATTGTRGAGGAGAATTTTTCTATTG3’
RevB 5’ TATTTATATAATTCACTTCTCCAATTGTC3’
In case amplification failed using the first couple of primers (Primers I), nested PCR was repeated using another couple of inner primers (Primers II).
Table 1: Primers used for nested PCR amplification of selected regions of gp120 HIV env.
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within the HIV-1 clade C subtype (Figure 1). The tree also showed a 
mixing of the Env sequences topology, independently of the patient 
region of origin. Moreover, nucleotide distances, implemented by 
Mega software, between viruses isolated from patients in Swaziland 
and viruses isolated from patients in South Africa, never exceeded 
17%, confirming a close relationship among the isolates from the two 
countries.  
Amino acid sequence alignment of the V1-V2, V3, and V4-V5 
regions showed high sequence variability in V1 and V4 sequences, 
for both amino acid substitutions and insertion/deletions of short 
amino acid sequences, mainly clustering in the C-terminal portion of 
both regions. The V2 and V5 regions were less variable, whereas the 
V3 region appeared well conserved among all the isolates. The high 
sequence variability originated also new PNGSs that clustered in the C 
terminal portion of the V1, V2 and V4 loops, in particular in the group 
of patients with chronic disease. 
The V3 region was extremely conserved for both amino acid 
sequence length and PNGSs number (median amino acid sequence 
length: 35aa; median PNGS number: 1) in all three disease stages, as 
previously described for HIV-1 subtype C virus [23] (data not shown). 
Therefore, due to its high degree of sequence conservation, the V3 
region was not included in the subsequent analyses of the characteristics 
of the gp120 variable sequences. 
A comparative box plot analysis of amino acid sequence length 
and PNGS number for each variable region is reported in figures 
2 and 3, respectively. Amino acid sequence length of the V1 and V4 
regions significantly increased in the CS patients when compared to 
that observed in patients with recent infection (RS) (p values of 0.0083 
and 0.0158, respectively) (figure 2). In addition, there was a statistically 
significant increase of the length of the V4 region in the group of LS 
patients compared to the RS patients group (p=0.0208). A reverse 
trend to shorter sequences (not statistically significant) was observed 
in LS individuals for both V1 and V4 regions. The V2 domain showed 
a somewhat inverted behaviour for length variability, although not 
statistically significant, since the sequence length tended to be slightly 
reduced in patients in the chronic disease stage when compared to 
individuals in the early and late disease stages. Finally, no statistically 
significant changes of amino acid length of the V5 region were present 
in each of the three groups of patients. 
Number of patients A I CD4+ T-cell count 
Range; [median](cell/μl)
RS 24 ≤0.80 NA*
CS 24 >0.80 418–881; [475]
LS 24 >0.80 17-199; [107.5]
*NA: Not Applicable. 
RS= Recent disease Stage; CS= Chronic disease Stage; LS= Late disease Stage.
Table 2: Classification of patients for disease stage according to AI and CD4+ T 
cell counts.
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Maximum likelihood phylogenetic analysis of HIV-1 variants was based on Env V3-V5 coding region (454 nucleotides). 
Tree was rooted by using the midpoint rooting method. The scale bar at the bottom indicates 7% nucleotide substitutions per site. 
The asterisk along a branch represents the bootstrap value (significant statistical support) >70% and p<0.001 in the zero-branch-length test.
Figure 1: Phylogenetic tree of the V3-V5 region.
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Significant p values are shown. The box plots denote the median, minimum and maximum values.
RS= Recent disease Stage; CS= Chronic disease Stage; LS= Late disease Stage.
Figure 2: Box plot analysis of aminoacid sequence length of V1, V2, V4 and V5 regions from patients at different disease stages.
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Figure 3: Box plot analysis of PNGSs number in V1, V2, V4 and V5 regions from patients at different disease stages
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The box plot analysis of PNGSs number is reported in figure 3. The 
number of PNGSs in the V1 region was significantly increased in CS 
patients, as compared to the RS patients group (p=0.0121). Furthermore, 
a slight not statistically significant, reduction of PNGSs number in V1 
during the late stage of disease was observed. In addition, a slight not 
statistically significant increase of PNGS number was observed for the 
V4 region in CS patients, compared to the RS patients group, while the 
number remained quite constant in the late infection stage. Neither 
statistically significant changes in the PNGSs number, nor trends, were 
present in the V2 and V5 regions when the three groups of patients 
were compared. 
A quantitative analysis of the PNGSs distribution revealed a stable 
presence of highly conserved PNGS, with an expression frequency 
≥0.70, irrespective of the disease stage, in the positions N136, N141, 
N156, N160, N186, N301, N386, N392, N397, and N463 of the 
corresponding HXBc2 sequence, distributed in all the five variable 
regions.
The qualitative analysis of the distribution of PNGSs among the 
different groups of patients is reported in figure 4. Besides the presence 
of the conserved PNGSs, a number of PNGSs with a lower expression 
level could be identified (referred as shifting PNGSs) [31]. These PNGS 
clustered in the C-terminal portion of V1 and V4 and, more moderately, 
in V2, in the CS group of patients, as compared to RS patients. Their 
mean expression frequency was <0.40 and only a few of them were 
still present in the group of patients in the late stage of disease. An 
exception was represented by the PNGS N406 in the V4 region that had 
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an intermediate behaviour, being expressed with a frequency <0.5 in 
the group of recently infected patients and increasing up to >0.7 in the 
groups of patients in the chronic and late disease stages.
To investigate if the variability patterns of amino acid length and 
PNGSs distribution were related, a regression analysis was carried out 
for each variable V1, V2, V4 and V5 domain, individually. The results 
indicated that a strong statistically significant positive correlation exists 
between length and PNGSs number, associated with positive regression 
coefficients.
To complete the analysis of sequence characteristics, we have 
calculated the net electric charge of each region, considering positive, 
negative and total electric charge distributions. Total electric charge 
(Qtot) of V1, V2 and V4 regions was found to be stable, the transition 
between different stages of disease being characterized by no significant 
changes. In the V5 region, the Qtot was lower in the CS patients disease, 
as compared to the groups of patients at both recent and late disease 
stage (figure 5), although the change was not statistically significant. 
However, when positive (Qpos) and negative (Qneg) electric charges 
were considered separately, a statistically significant increase of Qpos 
of V5 region was observed in the LS patients group, compared to the 
CS patients (p=0.027), whereas Qneg was similar in all the three groups 
(figure 5).
Discussion
We have conducted a cross-sectional study in patients at different 
disease stages in South Africa and Swaziland, where HIV-1 subtype C 
virus is predominant [57-59], with the aim to investigate changes of 
sequence characteristics of gp120 variable domains from virus variants 
obtained during the course of the disease. In order to avoid bias due 
to the pressure of antiretroviral drugs, we included in the study only 
patients naive for antiretroviral therapy. In addition, we excluded 
sampling bias due to collection of samples from two different countries, 
although from the same geographical region, by generating a Maximum 
Likelihood phylogenetic tree which indicated that the two subgroups 
were similar (nucleotide distance <10%). 
Our data on sequence analysis of gp120 variable domains confirmed 
an increase in overall amino acid variability in the chronic stage of the 
disease, predominantly in the V1 and V4 regions and, to a lower extent, 
in the V2 and V5 regions with the exception of the V3 region that was, 
instead, highly conserved, in all the three disease stages, in line with 
previously published studies [60].
The V1 and V4 sequence lengths significantly increased in the 
group of patients in the chronic disease stage, compared to those in the 
early stage. These data, among the few ones obtained in cross-sectional 
studies, support what was previously observed in longitudinal on HIV-
1 C and non-C subtypes, namely that HIV-1 isolates from patients with 
chronic disease are prone to length increase of the variable regions of 
gp120 which promotes resistance to neutralization [11,38,43,45,61-
63]. It is possible that these large V1/V2 domains contain epitopes 
recognized by neutralizing antibodies, in addition to those present in 
the V4 region of the HIV-1 C subtype [29]. This is further confirmed 
by recent data obtained on clade C variants indicating that shorter V1 
loops can expose the epitope recognized by anti-subtype C antibodies 
directed to the V1/V2 region, resulting in higher neutralization titres 
[64]. 
Our data also show a slight decrease of sequence length in the V1 
and V4 loops, during the late stage of the disease when compared to 
the chronic stage. We could speculate that sequence length reduction 
is a consequence of the reduced pressure of the immune response in 
late disease stage. In fact, variants bearing shorter V1 and V4 sequences 
may be favoured in late stages of the disease, as is the case with recent 
infections, when the HIV-specific immune response has not completely 
developed. This hypothesis is further supported by published data on 
subtype B, showing that the reduction of immunological pressure in 
the late disease stage may allow the re-emergence of previous existing 
variants [63]. In addition, a CD4+ T cell count cut-off of 150 cells/μl has 
been proposed to define the drop down of the selective pressure on Env 
variable domains [65], which is consistent with the CD4+ T cell count 
median value of 107.5 cells/μl in our patients in the late disease stage.
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The PNGSs distribution in the V1, V2, V4 and V5 domains 
during the course of the disease followed a pattern comparable to the 
one described for the sequences length. The existence of a positive 
correlation between length and PNGS number suggests that for the 
sequence length there could be a viral mechanism of evolution towards 
variants with a more glycosylated Env protein variants.
The distribution of conserved and shifting PNGS over the variable 
loops sequences also revealed some other intriguing possibilities. The 
analysis confirmed the presence of conserved PNGSs characterized by 
a steady high expression level (>70% throughout the disease stages), 
as previously described [66]. These PNGS are likely to be subjected 
to a negative selective pressure by the immune system, in agreement 
with the extensive literature data on their key role in envelope protein 
functionality [31,67]. Therefore, the correlation between sequence 
length variability and number of PNGSs is likely to affect the 
population of shifting PNGS. Zhang et al. have described these PNGS 
as being positioned in hot spot regions [31]. In agreement with these 
findings, our data show an extensive presence of shifting PNGSs in 
the V1 and V4, and, to a less extent, in the V2 loops that accumulate 
in the chronic disease stage and cluster in the C-terminal portion of 
the domains. These results are also in line with previously published 
studies on subtype A, B and C viruses, which describe an increase of 
the PNGSs number after the early-infection stage in the V1-V2 domain 
[38,42,43,68], although our data demonstrate that the distribution of 
“hot-spot” areas of shifting PNGS is different. Nevertheless, since HIV-
1 subtype C is phylogenetically more related to clade A than clade B, 
our data support the possibility of evolution of a subtype-specific glycan 
shield by the shifting PNGSs within the constraints posed by glycan-
dependent envelope functionality mediated by the more conserved 
PNGSs [27,31,46,69,70].
Taken altogether our data on sequence length and PNGS number 
variation suggest a major effect of the positive selective pressure driven 
by the host immune system on the V1 and V4 loops compared to the V2 
and V5 loops, indicating that the V1 and V4 regions could be among 
the main drivers of clade C HIV-1 virus evolution. This hypothesis is 
also in line with recent studies that identify the V1 loop as the major 
regulator of virus sensitivity towards neutralizing antibodies in subtype 
B [71] and point to the V4 loop of subtype C as a being a major target 
of neutralization activity [29].
Furthermore, our results suggest that the disease stage-related 
envelope evolution trend, previously observed in intra-individual 
dynamics, could be a distinctive mechanism of HIV-1 subtype C virus 
escape at the population level in Southern Africa.
It has been reported that differences in aminoacid charges correlate 
with resistance to neutralising antibodies [68]. In our study the Qtot of 
V1, V2 and V4 regions was found to be stable, throughout the course 
of the disease. Noteworthy, the V5 loop was characterized by a decrease 
of Qtot in the transition from early to chronic disease stage followed by 
an increase in the transition from chronic to late disease stage. This was 
associated with converse changes in Qpos, statistically significant in the 
transition from chronic to late disease stage. We can speculate that the 
V5 domain, while conserved in its sequence length and PNGSs number, 
undergoes significant changes in its net electrical charge, suggesting 
a crucial role of V5 charges in the 3D structure of Env, which could 
influence glycan packing and immune evasion, as it has been proposed 
previously [27-29].
In summary, our results have demonstrated the existence of a 
disease stage-related trend in the evolution of subtype C gp120 Env. 
Increased understanding of the exposure of different Env regions 
that have key function in virus infectivity and transmission may help 
current efforts to develop a preventative vaccine against HIV infection.
Sequence Data
All the 72 sequences generated from this study were deposited in 
GenBank under accession numbers JN120974-JN121117
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